Text Size
Home
About Dementia
What will early diagnosis of dementia look like by 2020?
The clinical / healthcare market
How will the impact of the project be measured?
What will be the impact of the project on the community?
Early and differential diagnosis
Clinical and Research Platforms
Technology solution
Research challenges
Multi-scale multi-factorial multiparadigm modelling
Track record of sharing
Research platforms
The industrial/commercial market
Technology Assessment, Market Analysis and Exploitation
Health technology assessment (HTA)
Project
Objectives
Benefits
Exploitation
Indicators
Work Packages
WP1
WP2
WP3
WP4
WP5
WP6
WP7
WP8
WP9
WP10
Research
People
Challenges
Platforms
Public Deliverables
Scientific Advisory Board
Partners
USFD
VTT
ESI
ASD
EMP
UIO
EMC
HIRS
PMS
ETHZ
KCL
PRH
STH
UCL
UEF
UMA
TO
ICL
EIBIR
SAB
Dissemination
Newsroom
Press Package
Press Releases
Videos
Newsletter
Publications
Dr. Paulien Aalten
Dr Paulien Aalten, neuropsychologist, co-ordinates the national AD biomarker studies and will contribute to WP1.
Website URL:
http://mhens.unimaas.nl/vervolgpagina/1055/4/Aalten/
Role:
Researcher
Contact Details
Title
E-mail:
p.aalten@maastrichtuniversity.nl
Address
P.O. Box 616, 6200 MD Maastricht The Netherlands
City
Maastricht
Country
Netherlands
Telephone
+31-43-3884104